Highest-materiality recent filing
Roy Rousso appointed Chief Business Officer effective July 1, 2026; will also serve as COO/CBO per consulting agreement.
BiomX exits phage therapy, pivots to defense/security via DFSL and Zorronet acquisitions
Discontinued all clinical trials; former BiomX Ltd. subsidiary filed for insolvency in Israel in Dec 2025.
Zorronet subsidiary signed 12-month framework agreement with Israel Railways to supply AI-powered animal detection stations.
BiomX accelerates option exercise, acquires 60% stake in DFSL for $750k cash, $3M note
Cash $750k, $3M convertible note (convertible at $12), 923k shares, and warrants for up to 4.6M shares at $12.
BiomX acquires ZorroNet, enters AI defense with $1.25M note and stock
Acquired 100% of ZorroNet, an Israeli AI-powered defense tech firm, for 1.3M shares and a $1.25M non-convertible note due July 2026.
BiomX shareholders approve 2026 Equity Incentive Plan at special meeting
Plan authorizes up to 1,390,000 shares of common stock plus annual 4% increase for 10 years.
BiomX secures option to buy defense-tech DFSL; $5M convertible note plus equity stakes up to 19.99%
Option to purchase 100% of Mandragola's DFSL shares; exercise after Mandragola acquires 60% of DFSL.
Notified for failing to meet minimum stockholders' equity requirements under Sections 1003(a)(i)-(iii) (thresholds $2M-$6M).
BiomX amends warrants to 1-year term at $1 exercise; outlines strategic reset
Warrant term shortened to expire Dec 31, 2026; exercise price reduced from $2.00 to $1.00 per share.
BiomX stockholders approve share issuance above 19.99% threshold for financing
At special meeting on March 11, 2026, stockholders approved issuance of common shares exceeding 19.99% of outstanding for conversion of Series Y preferred and warrants.
BiomX CEO and Chairman resign; Michael Oster appointed new CEO, Amir Shalom joins board
Jonathan Solomon resigned as CEO and director effective March 4, 2026; no disagreement with company.
BiomX CFO Wolfson, CDO Bassan and three directors resign; Rokach named CFO; meeting adjourned
CFO Marina Wolfson and CDO Merav Bassan resigned Feb 24, 2026; no disagreement with company.
BiomX: Alan Moses resigns from board; Guy Arieli and Shaked Ran appointed as directors
Alan Moses resigned from BiomX board on Feb 19, 2026 for personal reasons; no disagreements with company.
Two BiomX directors resign; Liat Bidas appointed to fill vacancy
Jonathan Leff and Jesse Goodman resigned from Board effective Feb 9 and Feb 11, 2026, for personal reasons; no disagreement with company.
BiomX deconsolidates Israel subsidiary after insolvency proceedings
BiomX Ltd. (wholly owned subsidiary) filed for insolvency in Israel on Jan 25, 2026; trustee appointed.
BiomX closes private placement, issues 3,300 Series Y Preferred shares; appoints director
Closed private placement of 3,300 Series Y Convertible Preferred shares and warrants on January 13, 2026.
BiomX subsidiary settles lease default with $800K payment, terminates Gaithersburg lease
Seventh Amendment terminates lease for BiomX subsidiary Adaptive Phage Therapeutics effective Dec 31, 2025.
BiomX raises $3.0M in private placement of Series Y Preferred and warrants
Gross proceeds $3.0M from sale of 3,300 shares Series Y Convertible Preferred (stated value $1,000/share) and warrants for 3.3M common shares.
BiomX subsidiary BiomX Ltd files for insolvency; Phase 2b study discontinued
Phase 2b study discontinued Dec 8 due to resource constraints exceeding available funds.
BiomX discontinues Phase 2b CF trial of BX004, cuts workforce, explores strategic alternatives
Independent DMC had recommended continuing Study with adjusted dosing, but company cites insufficient resources to execute alternative strategy.
BiomX reports FDA clinical hold continues; DMC recommends adjusted dosing for Phase 2b CF study
FDA continues evaluation of third-party nebulizer used in BX004 Phase 2b cystic fibrosis study; clinical hold remains.
BiomX approves 1:19 reverse stock split effective Nov 25, 2025
Board approved one-for-nineteen (1:19) reverse split on Nov 13, 2025.
BiomX Q3 net loss $9.2M; cash $8.1M; FDA feedback for BX011 and BX004 positive
Net loss of $9.2M in Q3 2025 vs net income of $9.6M in Q3 2024 due to warrant fair value changes.
BiomX: FDA clinical hold update – narrow nebulizer queries, no drug concerns; EU enrollment ahead
FDA provided additional narrow questions on third-party nebulizer; no concerns about BX004 drug product.
BiomX shareholders approve reverse stock split authorization and elect Class II directors
Elected Susan Blum, Dr. Jesse Goodman, and Gregory Merril as Class II directors until 2028.
FDA places clinical hold on BiomX's Phase 2b study of BX004 in CF due to nebulizer device
FDA hold pauses U.S. enrollment and screening for BX004 Phase 2b trial; no concerns about BX004 itself.
BiomX reports Q2 net loss $6.0M, cash $15.2M; BX211 shows >40% wound reduction in Phase 2
Cash and restricted cash $15.2M at June 30, 2025; estimated to fund ops into Q1 2026.
BiomX sets 2025 annual meeting for Oct 16; record date Aug 22, proposal deadline Aug 15
Annual Meeting scheduled for Thursday, October 16, 2025, with record date of August 22, 2025.
BiomX publishes Phase 1b/2a BX004 data in Nature Communications; shows 500-fold bacterial reduction
BX004 achieved 2.7 log10 (~500-fold) greater bacterial reduction vs placebo in CF patients with chronic P. aeruginosa infections.
BiomX posts updated corporate presentation; no material new disclosures
Posted updated slide deck in Investors section of website on June 9, 2025.
BiomX Q1 net loss $7.7M; cash $21.2M; BX004 Phase 2b topline Q1 2026
Net loss of $7.7M for Q1 2025, compared to $17.3M in Q1 2024; R&D expenses rose to $5.3M from $4.1M.
BiomX stockholders approve warrant exercise at special meeting
16,824,049 common shares represented at special meeting on April 21, 2025.
BiomX Announces Positive Phase 2 Results for BX211 in Diabetic Foot Osteomyelitis
BX211 showed statistically significant ulcer size reduction (PAR) at week 12 (p=0.046) and week 13 (p=0.052) vs placebo.
BiomX reports FY2024 results, $12M financing, Phase 2 DFO readout imminent
Phase 2 topline results for BX211 in diabetic foot osteomyelitis expected by end of March 2025.
BiomX closes $12M offering; shares outstanding increase to ~25M
Gross proceeds of ~$12M from registered direct offering, private placement, and warrant exercise.
BiomX raises $12M in combined offerings; funds BX004 Phase 2b to Q1 2026
Gross proceeds ~$12M from registered direct offering, private placement, and warrant exercise at $0.9306/share.
BiomX regains NYSE American listing compliance after prior deficiencies
Received notice from NYSE American on Dec 10, 2024 confirming compliance with continued listing standards.
Cash $24.7M as of Sep 30, 2024; company expects runway into Q4 2025.
BiomX units (PHGE.U) to cease trading on NYSE American Oct 25; warrants expire Oct 28
Mandatory separation of units into common stock and warrants effective Oct 25, 2024.
BiomX provides pipeline update: BX004 Ph2b results in Q3 2025, BX211 Ph2 results in Q1 2025
BX004 for CF: Phase 2b topline results expected Q3 2025 (60 patients, 2:1 randomized).
BiomX announces 1-for-10 reverse stock split effective August 26, 2024
Board approved 1-for-10 reverse split on Aug 8, 2024; effective at 12:01 a.m. ET on Aug 26, 2024.
BiomX gets NYSE American approval of compliance plan; deadline extended to Nov 2025
NYSE American accepted BiomX's plan to regain compliance with continued listing standards under Sections 1003(a)(i), (ii), (iii).
BiomX shareholders OK 750M authorized shares, reverse split up to 1:10
Authorized common shares increased from 120M to 750M, a 6.25x expansion.
BiomX files APT financials: net loss $16M, going concern doubt
APT net loss of $16.0M in 2023 and $23.6M in 2022; accumulated deficit $67.3M at Dec 31, 2023.
BiomX receives NYSE American delisting notice for equity deficiency; interim CFO departs
Stockholders' capital deficiency of $9.5M as of March 31, 2024; losses in five recent fiscal years.
On May 27, 2026, the Board of Directors of BiomX Inc. (“we,” “us,” “our,” “BiomX” or the “Company”) appointed Mr. Roy Rousso, to serve as the Chief Business Officer, effective July 1, 2026.
following Ms. Marina Wolfson’s return from maternity leave
Effective May 31, 2024, Mr. Avraham Gabay’s term as Interim Chief Financial Officer of the Company will conclude
Max materiality 0.90 · Median 0.65 · Most common event other_material